Physician profile
Mohammad Afzal
NPI 1245329069
$9,444.89
in general payments reported to CMS, 2019-2025
39 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,804 · 2020: $1,730 · 2021: $1,691 · 2022: $1,411 · 2023: $1,442 · 2024: $777 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,771 · Education: $39.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,770.58 |
| Education | $39.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,163.94 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $1,137.10 | 2019-2025 | |
| Amarin Pharma, INC. | $947.94 | 2019-2023 | |
| Lilly USA, LLC | $751.73 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $736.49 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $560.40 | 2019-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.22 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $414.21 | 2019-2024 | Rybelsus, Ozempic |
| Sunovion Pharmaceuticals INC. | $374.13 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $349.86 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $306.89 | 2019-2023 | Verquvo, Steglatro |
| Janssen Pharmaceuticals, INC | $261.65 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $230.48 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $220.51 | 2023-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $211.93 | 2020-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $148.63 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $140.82 | 2022 | |
| Abbvie INC. | $128.87 | 2021-2023 | Vraylar, Viberzi, Linzess |
| Astellas Pharma US INC | $111.99 | 2019-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $88.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $70.31 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $69.60 | 2019-2020 | |
| Chiesi USA, INC. | $55.47 | 2024 | Filsuvez |
| Xeris Pharmaceuticals, INC. | $54.49 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $54.31 | 2021-2023 | Eliquis |
| Corcept Therapeutics | $53.05 | 2023 | Korlym |
| Otsuka America Pharmaceutical, INC. | $52.51 | 2022-2023 | Rexulti |
| Sumitomo Pharma America, INC. | $37.61 | 2023 | Gemtesa |
| Viatris Specialty LLC | $30.66 | 2025 | Yupelri |
| Allergan, INC. | $30.53 | 2019-2020 | |
| Advanced Respiratory, INC | $22.15 | 2020 | |
| Acadia Pharmaceuticals INC | $17.16 | 2025 | Nuplazid |
| Horizon Therapeutics Plc | $16.60 | 2021 | |
| Reapplix INC. | $16.48 | 2025 | 3c Patch Kit - Box |
| Evoke Pharma, INC. | $15.28 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.96 | 2025 | Fanapt |
| Amgen INC. | $14.01 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.40 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Afzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.